Asia PacificBreaking News

Yicura BioMed closes first tranche of Series B funding from Gobi Partners

Hong Kong-based clinical-stage biotechnology company Yicura BioMed has completed the first close of its Series B funding round, led by Asia-focused venture capital firm Gobi Partners.

The company has not revealed the amount secured in the first close or the target size of the overall round. According to Yicura’s announcement on November 12, strategic investors from Wuxi and institutional investors based in Hong Kong also participated in the financing.

Yicura said it will deploy the proceeds towards advancing ICVAX, its therapeutic DNA vaccine candidate for HIV, and speeding up the development of cancer immunotherapy programmes across its vaccine and antibody pipelines.

Based at Hong Kong Science Park, the company was previously known as Immuno Cure. It develops immunotherapies using its PD-1-enhanced DNA vaccine and anti-Delta42PD1 antibody platforms. The latest funding extends Gobi Partners’ investment in the company following its participation in the 2023 Series A round.

According to Yicura, ICVAX has completed a randomised, placebo-controlled Phase I clinical trial involving people living with HIV who were receiving antiretroviral therapy. The study was approved by China’s National Medical Products Administration. The company described the safety and immunogenicity findings as favourable, although the latest financing announcement did not include the underlying clinical data.

Yicura intends to advance ICVAX into a Phase II clinical trial to assess its efficacy and determine whether the candidate can help achieve more sustained immune control of HIV. However, favourable safety or immune-response findings in Phase I do not demonstrate clinical efficacy, which will need to be evaluated in the planned next-stage study.

The company did not name the participating investors from Wuxi and Hong Kong, disclose Gobi Partners’ ownership stake, or provide a timeline for completing the Series B round.

Headquartered in Hong Kong and Kuala Lumpur, Gobi Partners said it manages $2 billion across more than 30 investment vehicles. These figures, along with the firm’s reported portfolio and exit numbers, are based on information provided by the company.

In 2023, Yicura, then operating as Immuno Cure, raised the first $12 million tranche of a planned $27 million Series A round. The financing was led by the AEF Greater Bay Area Fund, managed by Gobi Partners GBA, and also supported the development of the company’s DNA vaccine and antibody programmes.

The latest funding follows Yicura’s publication of Phase I data for ICVAX in July and its appointment of a contract research organisation in June for the planned Phase II study. The company has yet to announce when enrolment for the Phase II trial will commence.

 

 

Related Articles

Back to top button